Bilici, AhmetUysal, MükreminMenekşe, SerkanAkın, SemihYıldız, FatihTuran, MerveKaplan, Muhammet Ali2023-01-202023-01-202022Bilici, A., Uysal, M., Menekşe, S., Akın, S., Yıldız, F., Turan, M. ve diğerleri. (2022). Real-life analysis of efficacy and safety of everolimus plus exemestane in hormone receptor-positive, human epidermal growth factor receptor-2-negative metastatic breast cancer patients: A Turkish Oncology Group (TOG) study. Cancer Investigation, 40(2), 199-209.0735-79071532-4192https://www.tandfonline.com/doi/full/10.1080/07357907.2021.2017952https://hdl.handle.net/11468/11210Purpose This study evaluated the efficacy and safety of everolimus (EVE) plus exemestane (EXE) in hormone-receptor positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (MBC) patients in real-life settings. Methods Overall, 204 HR+, HER2- MBC patients treated with EVE + EXE after progressing following prior endocrine treatment were included. Overall survival (OS) and progression-free survival (PFS) and safety data were analyzed. Results The objective response rate, median PFS, and median OS were 33.4%, 8.9 months, and 23.4 months, respectively. Multivariate analysis revealed that negative progesterone receptor status was a significant determinant of poor treatment response (p = 0.035) and PFS (p = 0.024). The presence of bone-only metastasis was associated with better treatment response (p = 0.002), PFS (p < 0.001), and OS (p = 0.001). Conclusion We confirmed the favorable efficacy and safety profile of EVE + EXE for HR+, HER - MBC patients.eninfo:eu-repo/semantics/embargoedAccessEverolimusExemestaneMetastatic breast cancerHormone receptor-positiveHER - negativeEfficacyArticle402199209WOS:0007342583000012-s2.0-851218030553489496010.1080/07357907.2021.2017952Q3Q4